[REFERENCE TRANSLATION]

Please note that this translation is to be used solely as reference and the financial statements in this material are unaudited.

In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.

This translation is subject to change without notice. Linical Co., Ltd. shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation.

Consolidated Financial Results for the Year Ended March 31, 2023 (Japanese GAAP)

May 15, 2023

Company name : Linical Co., Ltd.

Stock Listing : Tokyo Stock Exchange

Code No. : 2183

URL : https://www.linical.co.jp/

Representative : Kazuhiro Hatano, President & Chief Executive Officer

Contact : Akihiro Takahashi, Executive Vice President, Chief Financial Officer

Scheduled date of Ordinary General Meeting of Shareholders : June 22, 2023

Scheduled date of start of dividend payment

Scheduled date of filing Financial Report of fiscal Year ended

Mar 2023

Preparation of supplementary materials for the financial

statements

Holding of presentation for the financial results

: Yes

: June 8, 2023

: June 23, 2023

(for institutional investors and analysts)

(All amounts are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Year Ended March 31, 2023 (April 1, 2022 to March 31, 2023)

(1) Consolidated Financial Results (cumulative)

(% figures show year-on-year change)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
Year Ended	(¥ million)	change(%)	(¥ million)	change(%)	(¥ million)	change(%)	(¥ million)	change(%)
March 31, 2023	12,516	8.3	1,256	15.7	1,283	8.4	1,004	27.1
March 31, 2022	11,555	12.4	1,085	139.5	1,183	101.1	790	46.4

(Note) Comprehensive income

Year Ended March 31, 2023:

¥1,354 million (16.8%)

Year Ended March 31, 2022:

¥1,159 million (54.9%)

Year Ended	Net income per share (¥)	Diluted net income per share	Return on Equity (%)	Ratio of Ordinary profit to Total assets (%)	Ratio of Operating income to Net sales (%)
March 31, 2023	44.47	_	14.2	7.7	10.0
March 31, 2022	35.00	_	12.9	7.6	9.4

(Reference) Equity method investment gain or loss: Ye

Year Ended March 31, 2023: - million

Year Ended March 31, 2022: - million

(2)Consolidated Financial Position

(2) Consolidated 1 Mariera	Total assets (¥ million)	Net assets (¥ million)	Shareholders' equity ratio (%)	Net asset per share (¥)
As of March 31, 2023	17,464	7,581	43.4	335.65
As of March 31, 2022	15,716	6,543	41.6	289.69

(Reference) Shareholder's equity:

As of March 31,2023: ¥ 7,581million

As of March 31,2022: ¥ 6,543million

(3) Consolidated Cash flow statement

Year Ended	Cash flow from operating activities (¥ million)	Cash flow from investing activities (¥ million)	Cash flow from financing activities (¥ million)	Cash and Cash equivalents at end of year (¥ million)
March 31,2023	1,839	Δ14	△957	7,042
March 31,2022	1,631	20	Δ951	5,985

2. Dividends

		Divide	nds per sh	are (¥)				Ratio of Total
						Total Amount		Amount of
						of Cash	Dividend	Dividends to
	1st Quarter	2nd Quarter	3rd Quarter	Fiscal	Total	Dividends	Payout Ratio	Shareholders'
	End	End	End	Year End	iotai	(annual)	(consolidated)	Equity
								(consolidated)
						(¥ million)	(%)	(%)
Year Ended	_	0.00	_	14.00	14.00	316	40.0	5.2
March 31, 2022		0.00		14.00	14.00	310	40.0	0.2
Year Ended	_	0.00	_	14.00	14.00	316	31.5	4.5
March 31, 2023		0.00		14.00	14.00	510	51.5	4.0
Year Ending								
March 31,	_	0.00	_	15.00	15.00		33.6	
2024(Forecast)								

3. Forecast of Consolidated Financial Result for the Year Ending March 31, 2024 (April 1, 2022 to March 31, 2024)

(% figures show year-on-year change)

	Net sa	les	Operating income Ordinary income		Profit attributable to owners of parent		Net income per share		
	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥)
Full year	13,300	6.3	1,400	11.4	1,400	9.1	1,008	0.4	44.63

Notes

(1) Changes in significant subsidiaries during the period(changes in specified subsidiaries that caused changes in scope of consolidation): No

New: - (Company Name) - Exclusion: - (Company Name) -

(2) Changes in accounting policies, accounting estimates and restatements

1) Changes in accounting policies resulting from the revision of the accounting standards and other regulations

2) Changes in accounting policies other than 1)

3) Changes in accounting estimates

4) Restatements

: Yes

: No

(3) Number of issued shares (Common share)

(a) Number of issued shares at the end of the period (including treasury shares)

 $\begin{array}{lll} \text{As of} & : 24,740,000 \text{ shares} \\ \text{March 31, 2023} & : 24,740,000 \text{ shares} \end{array}$

As of March 31, 2022

(b) Number of treasury shares at the end of the period

As of March 31, 2023 : 2,153,564 shares As of March 31, 2022 : 2,153,564 shares

(c) Average number of shares during the period

 Year Ended
 March 31, 2023
 : 22,586,436 shares

 Year Ended
 March 31, 2022
 : 22,586,436 shares

(Reference)

Non-Consolidated Financial Results for the Year Ended March 31, 2023

(April 1, 2022 to March 31,2023)

(1) Non-Consolidated Financial Results

(% figures show year-on-year change)

	Net sales		Operating income		Ordinary income		Net income	
Year Ended	(¥ million)	change(%)	(¥ million)	change(%)	(¥ million)	change(%)	(¥ million)	change(%)
March31, 2023	5,981	$\Delta 5.0$	737	45.7	1,058	54.7	839	132.9
March31, 2022	6,294	$\Delta 2.9$	506	80.1	684	69.3	360	36.7

Year Ended	Net income per share (¥)	Diluted net income per share
March31, 2023	37.17	_
March31, 2022	15.96	_

(2) Non-Consolidated Financial Position

	Total assets (¥ million)	Net assets (¥ million)	Equity ratio (%)	Net asset per share (¥)
As of March 31,2023	11,861	6,835	57.6	302.63
As of March 31,2022	11,577	6,276	54.2	277.88

(Reference) Shareholder's equity:

As of March 31,2023: \$6,835million As of March 31,2022: \$6,276million

* This release is outside the scope of the audit procedure by certified public accountants or audit firms.

This material contains business forecast and other forward-looking statements which are based on available information and certain assumptions that are considered reasonable at the time of preparation. Various factors may cause actual results to be materially different from those expressed in these forward-looking statements.

^{*} Explanation on appropriate use of forecast and other special items

	_	(Illousalius of yell)
	As of March 31, 2022	As of March 31, 2023
Assets		
Current assets		
Cash and deposits	5, 985, 618	7, 042, 100
Accounts receivable - trade and contrac	2, 917, 990	3, 427, 995
Prepaid expenses	197, 784	243, 216
Advances paid	987, 891	1, 037, 607
0ther	266, 645	270, 534
Allowance for doubtful accounts	△34, 842	△12, 786
Total current assets	10, 321, 087	12, 008, 667
Non-current assets		
Property, plant and equipment		
Facilities attached to buildings	95, 045	95, 439
Accumulated depreciation	△39, 854	△48, 388
Facilities attached to buildings, net	55, 190	47, 051
Tools, furniture and fixtures	319, 493	343, 673
Accumulated depreciation	△209, 128	△247, 379
Tools, furniture and fixtures, net	110, 365	96, 294
Leased assets	738, 008	830, 049
Accumulated depreciation	△239, 453	△348, 387
Leased assets, net	498, 554	481, 662
Total property, plant and equipment	664, 111	625, 008
Intangible assets	•	· ·
Goodwill	3, 406, 633	3, 384, 139
Other	159, 249	127, 054
Total intangible assets	3, 565, 883	3, 511, 194
Investments and other assets	· · ·	· · ·
Investment securities	347, 652	372, 806
Long-term prepaid expenses	5, 461	999
Guarantee deposits	366, 280	374, 096
Deferred tax assets	445, 992	571, 835
Total investments and other assets	1, 165, 387	1, 319, 737
Total non-current assets	5, 395, 381	5, 455, 940
Total assets	15, 716, 469	17, 464, 607

		(Illousalius of yell)
	As of March 31, 2022	As of March 31, 2023
Liabilities		
Current liabilities		
Short-term borrowings	600, 000	600, 000
Current portion of long-term borrowings	539, 976	539, 976
Accounts payable - other	533, 842	579, 604
Accrued expenses	402, 485	375, 821
Income taxes payable	193, 650	311, 502
Accrued consumption taxes	38, 747	86, 222
Advances received	2, 147, 272	2, 207, 195
Deposits received	688, 038	1, 700, 434
Provision for bonuses	171, 809	159, 922
Other	162, 279	174, 834
Total current liabilities	5, 478, 102	6, 735, 513
Non-current liabilities		
Long-term borrowings	2, 533, 566	1, 993, 590
Lease liabilities	430, 959	408, 621
Retirement benefit liability	689, 644	718, 354
0ther	41, 028	27, 313
Total non-current liabilities	3, 695, 198	3, 147, 878
Total liabilities	9, 173, 300	9, 883, 392
Net assets		· ·
Shareholders' equity		
Share capital	214, 043	214, 043
Retained earnings	6, 604, 985	7, 293, 144
Treasury shares	$\triangle 657, 461$	$\triangle 657,461$
Total shareholders' equity	6, 161, 567	6, 849, 726
Accumulated other comprehensive income		· ·
Valuation difference on available-for-		
sale securities	42, 339	78, 152
Foreign currency translation adjustment	322, 124	616, 973
Remeasurements of defined benefit plans	17, 138	36, 362
Total accumulated other comprehensive		
income	381, 601	731, 489
Total net assets	6, 543, 169	7, 581, 215
Total liabilities and net assets	15, 716, 469	17, 464, 607

		(Thousands of yell)
	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Net sales	11, 555, 088	12, 516, 998
Cost of sales	7, 943, 518	8, 355, 258
Gross profit	3, 611, 570	4, 161, 740
Selling, general and administrative expenses	* 1 2, 525, 666	*1 2,905,037
Operating profit	1, 085, 903	1, 256, 702
Non-operating income		
Interest income	598	1,807
Foreign exchange gains	100, 596	55, 723
Gain on valuation of investment securities	11, 781	_
Total non-operating income	112, 977	57, 531
Non-operating expenses		
Interest expenses	14, 180	12, 826
Loss on valuation of investment securities	_	18, 081
Other	1, 106	_
Total non-operating expenses	15, 286	30, 908
Ordinary profit	1, 183, 594	1, 283, 325
Extraordinary income		
Insurance claim income	_	115, 948
Gain on liquidation of subsidiaries	_	* 2 35, 378
Settlement recieved	* 3 162, 329	_
Total extraordinary income	162, 329	151, 326
Extraordinary losses		
Arbitration related expenses	* 4 145, 912	_
Information security expenses	* 5 168, 069	_
Business restructuring expenses	_	* 6 26, 651
Loss on cancellation of leases	_	29, 382
Total extraordinary losses	313, 981	56, 034
Profit before income taxes	1, 031, 942	1, 378, 618
Income taxes - current	249, 821	505, 460
Income taxes - deferred	△8, 367	△131, 211
Total income taxes	241, 454	374, 249
Profit	790, 487	1, 004, 368
Profit attributable to owners of parent	790, 487	1, 004, 368

(T)	1 0	\
(Thousand	is of	ven)
(III) usanc	io oi	y CII/

		(Thousands of yell)
	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Profit	790, 487	1, 004, 368
Other comprehensive income		
Valuation difference on available-for-sale securities	31, 254	35, 813
Foreign currency translation adjustment	323, 575	294, 849
Remeasurements of defined benefit plans, net of tax	13, 719	19, 224
Total other comprehensive income	368, 549	349, 887
Comprehensive income	1, 159, 037	1, 354, 256
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1, 159, 037	1, 354, 256
Comprehensive income attributable to non- controlling interests	_	_

	Shareholders' equity				
	Share capital	Retained earnings	Treasury shares	Total shareholders' equity	
Balance at beginning of period	214, 043	6, 142, 987	△657, 461	5, 699, 568	
Cumulative effects of changes in accounting policies		△12, 279		△12, 279	
Restated balance	214, 043	6, 130, 708	△657, 461	5, 687, 289	
Changes during period					
Dividends of surplus		△316, 210		△316, 210	
Profit attributable to owners of parent		790, 487		790, 487	
Net changes in items other than shareholders' equity					
Total changes during period		474, 277		474, 277	
Balance at end of period	214, 043	6, 604, 985	△657 , 461	6, 161, 567	

	Accumulated other comprehensive income				
	Valuation difference on available-for- sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	Total net assets
Balance at beginning of period	11, 084	△1, 451	3, 418	13, 052	5, 712, 620
Cumulative effects of changes in accounting policies					△12, 279
Restated balance	11, 084	△1, 451	3, 418	13, 052	5, 700, 341
Changes during period					
Dividends of surplus					△316, 210
Profit attributable to owners of parent					790, 487
Net changes in items other than shareholders'equity	31, 254	323, 575	13, 719	368, 549	368, 549
Total changes during period	31, 254	323, 575	13, 719	368, 549	842, 827
Balance at end of period	42, 339	322, 124	17, 138	381, 601	6, 543, 169

	Shareholders' equity				
	Share capital	Retained earnings	Treasury shares	Total shareholders' equity	
Balance at beginning of period	214, 043	6, 604, 985	△657, 461	6, 161, 567	
Changes during period					
Dividends of surplus		△316, 210		△316, 210	
Profit attributable to owners of parent		1, 004, 368		1, 004, 368	
Net changes in items other than shareholders'equity					
Total changes during period		688, 158		688, 158	
Balance at end of period	214, 043	7, 293, 144	△657, 461	6, 849, 726	

	Accumulated other comprehensive income				
	Valuation difference on available-for- sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	Total net assets
Balance at beginning of period	42, 339	322, 124	17, 138	381, 601	6, 543, 169
Changes during period					
Dividends of surplus					△316, 210
Profit attributable to owners of parent					1, 004, 368
Net changes in items other than shareholders'equity	35, 813	294, 849	19, 224	349, 887	349, 887
Total changes during period	35, 813	294, 849	19, 224	349, 887	1, 038, 046
Balance at end of period	78, 152	616, 973	36, 362	731, 489	7, 581, 215

-	-	
	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Cash flows from operating activities		
Profit before income taxes	1, 031, 942	1, 378, 618
Depreciation	168, 770	181, 321
Amortization of goodwill	271,810	318, 701
Amortization of long-term prepaid expenses	18, 198	3, 329
Business restructuring expenses	_	26, 651
Arbitration related expenses	145, 912	_
Information security expenses	168, 069	_
Settlement payments	△162, 329	_
Loss on cancellation of leases	_	29, 382
Loss (gain) on liquidation of subsidiaries	_	△35, 378
Insurance claim income	_	△115, 948
Increase (decrease) in provision for bonuses	$\triangle 6,634$	△13, 910
Increase (decrease) in allowance for	A F 910	A 95 .C45
doubtful accounts	$\triangle 5,210$	$\triangle 25,645$
Increase (decrease) in retirement benefit	40.041	20, 200
liability	49, 841	38, 082
Interest and dividend income	$\triangle 598$	$\triangle 1,807$
Interest expenses	14, 180	12, 826
Loss (gain) on valuation of investment	A 11 F01	10.001
securities	$\triangle 11,781$	18, 081
Foreign exchange losses (gains)	\triangle 89, 297	△102, 112
Decrease (increase) in trade receivables and		
contract assets	126, 088	$\triangle 413, 216$
Decrease (increase) in advances paid	225, 117	△29, 526
Decrease (increase) in prepaid expenses	△36, 874	△37, 390
Increase (decrease) in accounts payable -		
other	△133, 471	21, 008
Increase (decrease) in accrued expenses	△76, 180	△52, 08€
Increase (decrease) in advances received	96, 016	△100, 767
Increase (decrease) in deposits received	33, 508	999, 107
Other, net	398, 654	△28, 367
Subtotal	2, 225, 730	2, 070, 952
Interest and dividends received	598	1, 807
Interest paid	△14, 082	$\triangle 12,773$
Income taxes paid	△399, 361	$\triangle 280, 272$
Business restructuring expenses paid		$\triangle 26,651$
Loss on cancellation of leases paid	_	$\triangle 29,382$
Proceeds from insurance income	<u>_</u>	115, 948
Settlement received	162, 329	110, 940
Information security expenses paid	$\triangle 154, 144$	
	$\triangle 189, 275$	
Arbitration related expenses paid	△109, 215	
Net cash provided by (used in) operating	1, 631, 794	1, 839, 628
activities		
Cash flows from investing activities	4.50.000	A 40.000
Purchase of investment securities	△50,000	△10,000
Purchase of property, plant and equipment	$\triangle 45, 137$	△11,838
Purchase of intangible assets	△1, 336	△1, 396
Purchase of long-term prepaid expenses	△4, 011	△80
Proceeds from distributions from investment partnerships	52, 898	17, 604
Payments of guarantee deposits	$\triangle 32,478$	△10,740
Proceeds from refund of guarantee deposits	100, 822	2, 263
Net cash provided by (used in) investing		2, 200
Net cash provided by tused in threshing	20, 756	△14, 188

		(Thousands of yen)
	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	$\triangle 10,799$	_
Repayments of long-term borrowings	△539, 976	△539, 976
Dividends paid	△316, 042	∆316 , 038
Repayments of lease liabilities	△84, 729	△101, 317
Net cash provided by (used in) financing activities	△951, 548	△957, 331
Effect of exchange rate change on cash and cash equivalents	200, 414	188, 373
Net increase (decrease) in cash and cash equivalents	901, 417	1, 056, 481
Cash and cash equivalents at beginning of period	5, 084, 201	5, 985, 618
Cash and cash equivalents at end of period	5, 985, 618	7, 042, 100